Form 4 Filing for Yang Dajun

This filing details transactions made by Yang Dajun, Chairman and CEO of Ascentage Pharma Group International, on May 20-21, 2026. The transactions include the acquisition and vesting of restricted stock units (RSUs) and the acquisition of stock options. Specifically, 95,575 RSUs vested on May 21, 2026, and 298,195 RSUs were granted on May 20, 2026. Additionally, 298,194 stock options were acquired on May 20, 2026. The filing also notes indirect holdings through a trust and by Yang's spouse, with disclaimers of beneficial ownership beyond pecuniary interest. Yang Dajun also granted a power of attorney to Thomas J. Knapp and Leslie Brault to handle SEC filings and related matters.